Insights - Bellus had a call this morning (listen here) to discuss their Phase 1 data, released yesterday after market. As reported yesterday, at their anticipated therapeutic doses … Continue Reading
Read NowInsights - Amarin released detailed REDUCE-IT data this past Saturday and results were mixed. Although the Vascepa active arm showed strong data, the placebo arm used mineral oil, which … Continue Reading
Read NowInsights - Oncosec (ONCS) reported data from PICES combination trial with Keytruda this morning and came below expectations. ONCS stock is down more than 50% on the data, which … Continue Reading
Read NowInsights - Bellus is expected to report Phase 1 data, which will include taste, sometime in late November – early December. Below we analyze Merck’s Phase 2b … Continue Reading
Read NowInsights - Amarin (AMRN) will present data from their cardiovascular (CV) outcome REDUCE-IT trial on November 10. This data caused AMRN shares to jump from $3 – … Continue Reading
Read NowInsights - ONCS has two ipcoming catalysts with PICES data in November for metastatic melanoma and OMS-140 data for TNBC in December. Prior data (discussed below) leads … Continue Reading
Read NowInsights - Selecta released an 8-K after market today which disclosed that one of the patients in the SEL-403 trial died from a Grade 5 Serious Adverse … Continue Reading
Read Now
